SC
ALT icon

Sculptor Capital’s Altimmune ALT Stock Holding History

Sculptor Capital’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-276,700
Closed -$999K – 372
2025
Q4 		$999K Hold
276,700
– – 0.01% 277
2025
Q3 		$1.04M Buy
276,700
+125,700
+83% +$485K 0.01% 250
2025
Q2 		$584K Buy
151,000
+63,000
+72% +$341K 0.01% 263
2025
Q1 		$440K Buy
+88,000
New +$557K 0.01% 235

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sculptor Capital's ALT Position: Q1 2026 in Review

Sculptor Capital sold out of Altimmune (ALT) in Q1 2026, closing a stake of 276,700 shares — an estimated $999K sold.

Sculptor Capital first reported a position in ALT in Q1 2025 and held it in 4 quarters. The position peaked at $1.04M in Q3 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Sculptor Capital reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Sculptor Capital sold 276,700 Altimmune shares in Q1 2026, an estimated $999K.
  • Sculptor Capital first reported a position in Altimmune in Q1 2025 and held it in 4 quarters.
  • Sculptor Capital's Altimmune position peaked at $1.04M in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.